Abstract
The urinary excretion and pharmacokinetics of acrolein (ACRO) and its parent drug cyclophosphamide (CP) were investigated in 16 randomly selected bone marrow transplant (BMT) recipients when CP was used for conditioning. Patients suffering from aplastic anemia (n = 3) received a 4-day course of CP at a dose of 50 mg/kg daily infused intravenously (i.v.) over 1 h. Patients with leukemia (n = 13) were given either a combination of busulphan followed by CP at a dose of 50 mg/kg infused i.v. over 1 h for 4 days, or CP at a dose of 60 mg/kg by i.v. infusion over 1 h daily for 2 days followed by total body irradiation. Serial plasma samples and urine were collected after the start of the first CP dose. CP was analyzed by capillary gas chromatography, whereas ACRO was measured in urine by liquid chromatography. The plasma concentration-time data for CP conformed to the two-compartment model and the mean and s.e.m. values of α, β, Vss, total clearance, and renal clearance observed were 1.29 (0.31) h−1, 0.17 (0.03) h−1, 0.67 (0.13) l/kg, 0.14 (0.02) l/h.kg, and 0.0188 (0.0052) l/h.kg, respectively. The mean and s.e.m. values of fraction of CP excreted in the form of ACRO during this interval (fmu) and ratio of the 24-h urinary concentration of ACRO/creatinine (Cmu(n)) were 1.96 (0.35%) and 9.11 (2.19) μg of ACRO/mg of creatinine, respectively. Two patients developed hemorrhagic cystitis (HC). Each of these two patients excreted significantly (P < 0.01) more acro in the first and second 4-h urine collection periods. however, there was no significant difference in fmu or Cmu(n) of ACRO between either of these two patients and the rest. This suggests that the rate of appearance of ACRO in urine is more crucial for developing HC than the cumulative amount excreted.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Al-Rawithi, S., El-Yazigi, A., Ernst, P. et al. Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients. Bone Marrow Transplant 22, 485–490 (1998). https://doi.org/10.1038/sj.bmt.1701355
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701355
Keywords
This article is cited by
-
Novel insights into the mechanism of cyclophosphamide-induced bladder toxicity: chloroacetaldehyde’s contribution to urothelial dysfunction in vitro
Archives of Toxicology (2019)
-
Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival
Bone Marrow Transplantation (2015)
-
Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT
Bone Marrow Transplantation (2012)
-
Intravesical epinephrine preserves uroplakin II expression in urinary bladder from cyclophosphamide-induced rat cystitis
Naunyn-Schmiedeberg's Archives of Pharmacology (2012)
-
Preservation of uroplakins by 2-mercaptoethanesulfonate in cyclophosphamide-induced rat cystitis
Archives of Toxicology (2011)